Aeon Biopharma CAO Jennifer Sy buys $19,984 of company stock
Jennifer Sy, the Chief Accounting Officer of AEON Biopharma, Inc., made a notable stock purchase on November 19, 2026, acquiring 153,846 shares of the company's Class A Common Stock. This transaction valued at $19,984 was conducted at prices between $0.1290 and $0.1300 per share, resulting in a weighted average price of $0.1299.
Ms. Sy's ownership of AEON Biopharma now stands at 1,655,022 shares. The company's stock has been trading close to its 52-week low of $0.11, dropping 19.61% over the past week and 88.82% year-to-date. Despite this downturn, InvestingPro analysts deem AEON Biopharma undervalued at present. The company's balance sheet shows more cash than debt, but the financial health score is marked as "WEAK."
Further updates include a modification in the terms of AEON Biopharma's outstanding two-year milestone warrants, which lowered the exercise price for both Class A common stock and pre-funded warrants to $0.20 and $0.1999, respectively, effective November 2, 2026. This adjustment is anticipated to generate $6.2 million. Additionally, Laidlaw has begun covering AEON Biopharma with a Buy rating and a price target of $1.80.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.